Loading

Bionoxx Inc.

June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 1
Bionoxx Inc. (Bionoxx), founded in 2016, is committed to demystifying the functional heterogeneity of circulating neutrophils in cancer as well as immune-related diseases. Based on BNX-IFS (Immune Function States), a unique assay that detects activated neutrophils implicated in impaired immune homeostasis, we have shown effective immunomodulatory strategies in the treatment of ICI-resistant tumor mice model and viral sepsis mice model. Employing this strategy, Bionoxx obtained USFDA acceptance to proceed with a first-in-human trial with Immuno-Oncology (IO) virotherapy (mOTS-400) aimed at overcoming ICI resistance. BNX-IFS's ability to detect specific immune states in circulating blood is essential for tailoring immunomodulatory strategies across immune-related conditions. BNX is actively seeking partnerships with leading pharmaceutical companies to further our mission and make significant strides in the field of immunotherapy.
Bionoxx Inc.
Company Website: http://www.bionoxx.com
Lead Product in Development: immuno-oncology therapy

Company HQ City

Seongnam

Company HQ State

Gyeonggi-do

Company HQ Country

Korea, Republic of

CEO/Top Company Official

Soobeum Yi

Development Phase of Primary Product

Phase I
Speakers
Euna Cho, PhD
Director
Bionoxx Inc.
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS